Contact us

SENVELGO^® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.

Before using this product, it is important to read the entire product insert, including the boxed warning.


Cats treated with SENVELGO^® may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death.

Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO^®.


Do not use SENVELGO^® in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus.

The use of SENVELGO^® in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO^®, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.


Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO^® should prompt immediate discontinuation of SENVELGO^® and assessment for diabetic ketoacidosis, regardless of blood glucose level.

SENVELGO^® should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO^® in a secure location out of reach of children, dogs, cats, and other animals to avoid accidental ingestion or overdose. 

For more information, please see full prescribing information.